Eckert & Ziegler Soars Higher: Continues Growth Streak Post Successful 2023 Fiscal Year

• Eckert & Ziegler SE had sales of €246.1 million in 2023, with an 11% increase from the previous year
• EBIT from continuing operations before special items was €46.9 million, and net profit for the year was €26.3 million
• Sales in the Medical segment increased by 27% to €115.2 million, driven by demand for radiopharmaceuticals
• Sales in the Isotope Products segment remained at €130.9 million
• The Executive Board expects sales of nearly €265 million and EBIT of around €50 million for 2024
• Eckert & Ziegler SE is a leading specialist for isotope-related components in nuclear medicine and radiation therapy, with shares listed in the TecDAX index of Deutsche Börse.

The next important date, Publication Annual Financial Report, at Eckert & Ziegler is on 22.03.2024.

The price of Eckert & Ziegler at the time of the news was 40,26EUR and was down -0,05 % compared with the previous day.
15 minutes after the article was published, the price was 40,85EUR this corresponds to a plus of +1,47 % since publication.
At this time, the index SDAX was at 13.978,25PKT (+0,65 %).

Eckert & Ziegler

+1,43 %

+11,46 %

-3,01 %

-19,03 %

-21,59 %

-51,79 %

+95,53 %

+497,70 %

+800,54 %

ISIN:DE0005659700WKN:565970

• Intraday
• 5 Tage
• 1 Monat
• 3M
• 1 Jahr
• 3J
• 5J
• 10J
• Max